B.Sc. University Mohamed V, Rabat, Morocco
M.Sc. Université du Québec a Montréal
Ph.D. Université de Montréal
Post-Doc. McGill University
Post-Doc. The Vancouver Prostate Centre
Senior Research Scientist, Vancouver Prostate Centre
Professor, Department of Urologic Sciences, University of British Columbia
Canada Research Chair in Cancer Therapy Resistance
Dr. Zoubeidi’s research program aims at uncovering how androgen receptor activity controls phenotypic plasticity, which has been associated with the clinically relevant problem of drug resistance in prostate cancer (PCa). Her multifaceted program addresses the importance of various signaling pathways in this inherently heterogeneous disease. Importantly, amplification of different signaling pathways may be unique to an individual and their disease; therefore, her research program is designed to identify and understand common signaling nodes responsible for the emergence of resistance to ultimately design the best combination therapy to guide clinical decisions.
As a critical tool in her arsenal to investigate the highly clinically relevant problem of treatment resistance to anti-androgens, the mainstay therapy for advanced PCa, she has developed a unique set of reagents and resources. These include tumours and cell lines resistant to the newest anti-androgen, Enzalutamide (ENZ), making her highly competitive globally in this field of research. This model recapitulates patient heterogeneity of ENZ treatment; while continued AR activity occurs in CRPC, alternative, AR-independent (or non-driven) phenotypes of disease such as Neuroendocrine PCa (NEPC) or anaplastic PCa are emerging in the clinic.
She has been very successful as a young investigator, establishing national and international collaborations on research projects and grants from the public and private sector. This has resulted in over 100 published papers/abstracts, 6 patent applications, as well as funding as both a principal investigator and co-investigator on grants focused on understanding the molecular mechanisms of advanced PCa.
She has been recognized as an outstanding up-and-coming scientist by the Prostate Cancer Foundation-USA (PCF) and was awarded the prestigious PCF Young Investigator Award in 2010. She was the only Canadian holding this award in 2010 class. As a mentor, she nominated her post-doctoral fellow, Dr. Bishop, for the same award; Dr. Bishop was the only Canadian Awardee in the 2013 competition. Dr. Zoubeidi holds prestigious awards from the Terry Fox and Michael Smith Foundations for Health Research, from which she received funding as a New Investigator and Research Scholar. These highly competitive awards and most recently acquired PCa Canada Movember grant will support her research for a total of 10 years. Recently she was awarded the Faculty of Medicine Distinguished Achievement Award in Overall Excellence - Early Career, University of British Columbia (2014) and Research Teaching Award for Excellence in Basic Science, Department of Urologic Sciences, Faculty of Medicine, University of British Columbia (2014). Moreover, her track record of research excellence is underscored by numerous accolades from the American Association for Cancer Research, the American Urological Association, the Northwest Urological Society and others. She had the honor of being invited to speak at numerous national and international conferences on molecular mechanisms and drug targets of PCa, including AACR and CCRC and as a visiting professor at different Universities. She serves on several grant panel review committees including Prostate Cancer Canada, the Canadian Institute of Health Research and Prostate Cancer Foundation USA. She is a member of the editorial board of Endocrine Related Cancer and ad hoc reviewer for numerous journals including EMBO, Oncogene, and the AACR journals.